Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia

BACKGROUND: Imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia leading to significant reductions of BCR-ABL1 transcript levels in peripheral blood. OBJECTIVE: To evaluate the response to imatinib mesylate treatment (400 mg/day) in Brazilian patients in the chronic phase o...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieira-Mion, Ana Lucia, Pereira, Noemi Farah, Funke, Vaneuza Araujo Moreira, Pasquini, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568590/
https://www.ncbi.nlm.nih.gov/pubmed/28830599
http://dx.doi.org/10.1016/j.bjhh.2017.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568590/
https://www.ncbi.nlm.nih.gov/pubmed/28830599
http://dx.doi.org/10.1016/j.bjhh.2017.04.007

Ejemplares similares